MicroRNA-26a promotes tumor growth and angiogenesis in glioma by directly targeting prohibitin.

Xu Qian,Peng Zhao,Wei Li,Zhu-Mei Shi,Lin Wang,Qing Xu,Min Wang,Ning Liu,Ling-Zhi Liu,Bing-Hua Jiang
DOI: https://doi.org/10.1111/cns.12149
2013-01-01
CNS Neuroscience & Therapeutics
Abstract:Backgrounds and AimsGlioma accounts for the majority of primary malignant brain tumors in adults. Upregulation of microRNA-26a (miR-26a) has been observed in glioma. However, the biological function and molecular mechanism of miR-26a in glioma remain to be elucidated. MethodsGlioma cells stably overexpressing or down-expressing miR-26a were analyzed for both in vitro and in vivo biological functions. Novel target of miR-26a was identified by bioinformatics searching and molecular biological assays. Glioma specimens and normal brain tissues were analyzed for both expression levels of miR-26a and its target. ResultsForced expression of miR-26a in glioma cells significantly increased both growth rate and colony formation in vitro and tumor growth and angiogenesis in vivo, while reduced expression of miR-26a played opposite roles. MiR-26a directly targeted prohibitin (PHB) whose expression levels were downregulated in glioma specimens. The levels of miR-26a were inversely correlated with PHB expression levels in glioma samples and strongly correlated with clinical WHO grades of glioma. ConclusionThese results reveal that miR-26a regulates PHB and promotes glioma progression both in vitro and in vivo and that miR-26a and its target PHB are associated with glioma development, which can be helpful in developing microRNA-based treatment for glioma in the future.
What problem does this paper attempt to address?